GBX1,908 support anchors GSK stock in tight range

Traders Union
All News
Financial News
GSK down 0.49% as Nuvalent deal looms

Highlights

GSK has launched a USD10.6 billion tender offer to acquire Nuvalent, targeting strategic expansion into oncology therapeutics.
Nuvalent's board supports the acquisition while GSK continues share buybacks to stabilize investor sentiment during major corporate changes.
GSK trades below key short- and medium-term averages with a bearish tone, expected to range between GBX1,908 and GBX1,972.

Oncology expansion and buybacks as acquisition shifts risk outlook

GSK has launched a tender offer to acquire Nuvalent, a US-based cancer drug developer, for USD10.6 billion, with withdrawal rights expiring on July 14 and Nuvalent's board supporting the move, according to Lse Co and Tipranks. This potential acquisition represents a strategic expansion into oncology therapeutics and could alter growth expectations and risk sentiment ahead of regulatory and antitrust outcomes. In parallel, GSK has been actively reducing its public float through share buybacks—acquiring over 8 million shares since May 11, including recent purchases executed via Citigroup—which may provide a stabilizing effect in the face of major ongoing corporate events.

Divergent momentum persists as technical signals highlight oversold zone

Technically, GSK is trading below the MA-20 at GBX1,955 and the MA-50 at GBX1,943 on the H1 chart, but remains above the MA-200 at GBX1,875 on the daily timeframe. Immediate resistance is highlighted by the Ichimoku Kijun line at GBX1,947. The Moving Average Convergence Divergence (MACD) presents a strong buy signal, while the Average Directional Index (ADX) is neutral, suggesting divergent momentum. The Relative Strength Index (RSI) at 39.55 flags sell conditions, and measurements from the Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power all point to oversold or seller-led dynamics. The Awesome Oscillator is neutral and does not currently signal a directional bias.

Downside break risk increases as recovery odds diminish

In the short term, GSK is expected to trade within a volatility band of GBX1,908 to GBX1,972. The probability of a move to the upside stands at 40%, whereas a pullback below the lower boundary is somewhat more likely at 60%. A push above GBX1,947 could open the door to further recovery, while a break under GBX1,908 would likely trigger renewed selling momentum.

Viktoras Karapetjanc, expert at Traders Union, sees GSK’s bid to acquire Nuvalent as a decisive step to strengthen its oncology segment and US footprint. He believes steady share buybacks reflect management’s confidence and may help stabilize sentiment around this major deal. Technical signals remain mixed, but macro and fundamental drivers favor a constructive stance. "If GSK can sustain above GBX1,908 and deliver on this strategic acquisition, I expect improved market confidence and a renewed uptrend."

Earlier, analysts noted that GSK exhibited bullish technical momentum supported by share buybacks but faced risks from overbought conditions. The current shift to seller-led indicators and the impending Nuvalent acquisition introduce new downside risks, making sustained closes above immediate resistance a critical signal for stabilization.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.